Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

With the increasing emergence of viral infections worldwide, researchers are working to develop new and non-conventional treatments for infectious diseases. This is particularly true for SARS-CoV-2, which initiated a pandemic in 2019. With a focus on coronavirus, this book provides an overview of antiviral agents and new approaches to drug design. It includes five chapters that address new avenues for drug discovery, reprofiling of current drugs, computer-aided drug design, and more.

Antiviral agents.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

With the increasing emergence of viral infections worldwide, researchers are working to develop new and non-conventional treatments for infectious diseases. This is particularly true for SARS-CoV-2, which initiated a pandemic in 2019. With a focus on coronavirus, this book provides an overview of antiviral agents and new approaches to drug design. It includes five chapters that address new avenues for drug discovery, reprofiling of current drugs, computer-aided drug design, and more.

Antiviral agents.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antiviral Agents

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Glecaprevir/pibrentasvir (GP) is a fixed-dose combination of two pan-genotypic direct-acting antiviral (DAA) drugs: glecaprevir, a nonstructural viral protein 3/4A (NS3/4A) protease inhibitor; and pibrentasvir, a nonstructural viral protein 5A (NS5A) inhibitor. GP is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis (Table 2). The recommended dose is three tablets (glecaprevir 300 mg / pibrentasvir 120 mg) once daily for 8 to 16 weeks, depending on the patient's prior treatment experience, genotype and whether cirrhosis is present. At the time of submission, the manufacturer submitted a price of 797.62 for three tablets. This price was reduced by the manufacturer during the review to 714.29 for three tablets, reflecting an approximate 10% reduction in the original price, and corresponding to 40,000 for an 8-week (56-day) treatment,

Antiviral agents.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

With the increasing emergence of viral infections worldwide, researchers are working to develop new and non-conventional treatments for infectious diseases. This is particularly true for SARS-CoV-2, which initiated a pandemic in 2019. With a focus on coronavirus, this book provides an overview of antiviral agents and new approaches to drug design. It includes five chapters that address new avenues for drug discovery, reprofiling of current drugs, computer-aided drug design, and more.

Antiviral agents.